Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
73.26 USD | -0.58% | -2.73% | -9.57% |
Mar. 18 | Gilead Sciences Receives a Shareholder Proposal from John Chevedden | CI |
Mar. 18 | Gilead Sciences Receives a Shareholder Proposal from David Bahnsen | CI |
Evolution of the average Target Price on Gilead Sciences, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Gilead Sciences, Inc.
Wells Fargo Securities | |
Mizuho Securities | |
Truist Securities | |
RBC Capital Markets | |
Oppenheimer | |
UBS | |
Piper Sandler | |
TD Cowen | |
Cantor Fitzgerald | |
Leerink Partners | |
Barclays | |
Morgan Stanley | |
Deutsche Bank Securities | |
BofA Securities | |
HSBC | |
Goldman Sachs | |
BMO Capital | |
SVB Securities LLC | |
Cowen | |
Maxim | |
JPMorgan Chase | |
Argus | |
SVB Leerink | |
Credit Suisse | |
Bernstein | |
Redburn | |
DZ BANK | Elmar Kraus |
EPS Revisions
- Stock
- Equities
- Stock Gilead Sciences, Inc. - Nasdaq
- Consensus Gilead Sciences, Inc.